MedTrace Logo

ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors

NCT01154426 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2015-07-02

No results posted yet for this study

Summary

This phase I trial is studying the side effects and best dose of giving ABT-888 together with gemcitabine hydrochloride in treating patients with advanced solid tumors. ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving ABT-888 together with gemcitabine hydrochloride may kill more tumor cells.

Conditions

  • Adult Solid Neoplasm
  • BRCA1 Mutation Carrier
  • BRCA2 Mutation Carrier

Interventions

OTHER

Diagnostic Laboratory Biomarker Analysis

Correlative studies

DRUG

Gemcitabine Hydrochloride

Given IV

OTHER

Pharmacological Study

Correlative studies

DRUG

Veliparib

Given orally

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Ronald Stoller · University of Pittsburgh Cancer Institute (UPCI)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2013-10-31
Completion
2013-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01154426 on ClinicalTrials.gov